Published in Protein Sci on May 01, 2006
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature (2012) 1.68
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem (2007) 1.47
Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin (2014) 1.15
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Evolution of hormone signaling in elasmobranchs by exploitation of promiscuous receptors. Mol Biol Evol (2008) 1.09
Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface (2012) 1.01
Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor. Asian J Androl (2010) 0.90
Androgens in pregnancy: roles in parturition. Hum Reprod Update (2014) 0.89
Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening. PLoS Comput Biol (2009) 0.88
Nuclear hormone receptor signaling in amphioxus. Dev Genes Evol (2008) 0.88
Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors. J Chem Inf Model (2015) 0.86
Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int J Mol Sci (2013) 0.86
Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain. Mol Endocrinol (2009) 0.85
Androgen receptor gene rearrangements: new perspectives on prostate cancer progression. Curr Drug Targets (2013) 0.85
Constitutive activity of the androgen receptor. Adv Pharmacol (2014) 0.84
Studies of metabolite-protein interactions: a review. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.84
Chaperones and the maturation of steroid hormone receptor complexes. Oncotarget (2011) 0.81
Ultrafast protein structure-based virtual screening with Panther. J Comput Aided Mol Des (2015) 0.79
Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery. J Comput Aided Mol Des (2013) 0.77
A computational approach to evaluate the androgenic affinity of iprodione, procymidone, vinclozolin and their metabolites. PLoS One (2014) 0.77
Ecdysteroids: A novel class of anabolic agents? Biol Sport (2015) 0.77
X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids. J Biol Chem (2012) 0.77
The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications. J Anal Toxicol (2011) 0.76
Identification and Characterization of the Androgen Receptor From the American Alligator, Alligator mississippiensis. Endocrinology (2015) 0.75
X-ray crystal structure of the ancestral 3-ketosteroid receptor-progesterone-mifepristone complex shows mifepristone bound at the coactivator binding interface. PLoS One (2013) 0.75
Nestorone® (NES) a Novel Progestin for Non-oral Contraception: Structure-activity Relationships and Brain Metabolism Studies. Endocrinology (2016) 0.75
Crystallization and preliminary X-ray analysis of the human androgen receptor ligand-binding domain with a coactivator-like peptide and selective androgen receptor modulators. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.75
Moving Beyond Active-Site Detection: MixMD Applied to Allosteric Systems. J Phys Chem B (2016) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature (1992) 36.50
The nuclear receptor superfamily: the second decade. Cell (1995) 24.99
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng (1995) 19.22
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
Monte Carlo-minimization approach to the multiple-minima problem in protein folding. Proc Natl Acad Sci U S A (1987) 5.84
A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol (1996) 4.69
Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev (1995) 4.22
Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov (2004) 4.19
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Atomic structure of progesterone complexed with its receptor. Nature (1998) 2.83
Biological actions of androgens. Endocr Rev (1987) 2.81
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Swiss-PDB Viewer (Deep View). Brief Bioinform (2001) 2.48
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A (2001) 2.44
Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell (2004) 2.38
Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol (2004) 1.91
The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem (2004) 1.66
Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res (1994) 1.59
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
Current concepts in anabolic-androgenic steroids. Am J Sports Med (2004) 1.48
Regulation of androgen action. Vitam Horm (1999) 1.34
Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem (2002) 1.30
Specific recognition of androgens by their nuclear receptor. A structure-function study. J Biol Chem (2000) 1.16
Chloride channels of glycine and GABA receptors with blockers: Monte Carlo minimization and structure-activity relationships. Biophys J (2000) 1.13
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology (2002) 1.12
Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom (2004) 1.11
The androgen receptor: a mediator of diverse responses. Front Biosci (1996) 1.09
Androgen resistance due to mutation of the androgen receptor. Clin Invest Med (1992) 1.08
Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J Endocrinol (2005) 0.91
Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modified denaturing gradient gel electrophoresis technique. Mol Endocrinol (1992) 0.88
Coactivators and corepressors as mediators of nuclear receptor function: an update. Mol Cell Endocrinol (1998) 0.87
Monte Carlo-minimized energy profile of estradiol in the ligand-binding tunnel of 17 beta-hydroxysteroid dehydrogenase: atomic mechanisms of steroid recognition. Proteins (2000) 0.86
Tetrahydrogestrinone is an androgenic steroid that stimulates androgen receptor-mediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized male rats. Endocrinology (2005) 0.85
Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Biochem Biophys Res Commun (1993) 0.85
Androgen receptor in human skin cytosol. J Clin Endocrinol Metab (1981) 0.81
Mapping of steroids binding to 17 beta-hydroxysteroid dehydrogenase type 1 using Monte Carlo energy minimization reveals alternative binding modes. Biochemistry (2005) 0.80
Tetrahydrogestrinone is a potent androgen and progestin. J Clin Endocrinol Metab (2004) 0.80
Eight novel mutations of the androgen receptor gene in patients with androgen insensitivity syndrome. J Hum Genet (2001) 0.79
Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am J Obstet Gynecol (1997) 0.78
Bilateral testicular tumors in androgen insensitivity syndrome. Int J Urol (2000) 0.77
Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med (2010) 6.13
Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res (2008) 2.44
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (2015) 2.41
Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab (2010) 2.01
High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol (2011) 1.81
Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab (2011) 1.71
Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol (2012) 1.65
Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab (2008) 1.58
Frailty in relation to variations in hormone levels of the hypothalamic-pituitary-testicular axis in older men: results from the European male aging study. J Am Geriatr Soc (2011) 1.57
The relationships between sex hormones and sexual function in middle-aged and older European men. J Clin Endocrinol Metab (2011) 1.53
Reductions in glucose among postmenopausal women who use and do not use estrogen therapy. Menopause (2013) 1.50
Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. Psychoneuroendocrinology (2011) 1.47
Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab (2010) 1.42
Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. J Invest Dermatol (2005) 1.41
Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older European men. Pain (2011) 1.41
Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab (2003) 1.31
Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab (2009) 1.23
Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol (2004) 1.22
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab (2004) 1.19
The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab (2007) 1.19
Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J Mol Biol (2003) 1.11
Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab (2012) 1.08
To the Editor. Menopause (2016) 1.07
Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab (2009) 1.06
Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. Mol Endocrinol (2004) 1.05
Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J Immunol (2005) 1.03
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res (2006) 1.03
Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases. Urology (2007) 1.03
Evidence for geographical and racial variation in serum sex steroid levels in older men. J Clin Endocrinol Metab (2010) 1.02
The intracrine sex steroid biosynthesis pathways. Prog Brain Res (2010) 1.01
The crystal structure of human Delta4-3-ketosteroid 5beta-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism. Biochemistry (2008) 1.00
Endogenous sex hormone changes in postmenopausal women in the diabetes prevention program. J Clin Endocrinol Metab (2012) 1.00
Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab (2009) 0.99
Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab (2013) 0.99
Comparisons of immunoassay and mass spectrometry measurements of serum estradiol levels and their influence on clinical association studies in men. J Clin Endocrinol Metab (2013) 0.97
Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol (2005) 0.97
Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem (2008) 0.96
Quantitative appreciation of steroidogenic gene expression in mouse tissues: new roles for type 2 5alpha-reductase, 20alpha-hydroxysteroid dehydrogenase and estrogen sulfotransferase. J Steroid Biochem Mol Biol (2005) 0.96
Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J Clin Endocrinol Metab (2008) 0.95
Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J Biol Chem (2006) 0.95
Loop relaxation, a mechanism that explains the reduced specificity of rabbit 20alpha-hydroxysteroid dehydrogenase, a member of the aldo-keto reductase superfamily. J Mol Biol (2004) 0.95
Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol (2005) 0.93
The ITIM-bearing CLECSF6 (DCIR) is down-modulated in neutrophils by neutrophil activating agents. Biochem Biophys Res Commun (2003) 0.92
Crystal structures of human Delta4-3-ketosteroid 5beta-reductase (AKR1D1) reveal the presence of an alternative binding site responsible for substrate inhibition. Biochemistry (2008) 0.91
Role of androgens in women's sexual dysfunction. Menopause (2010) 0.91
Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. J Histochem Cytochem (2009) 0.90
Are women with Sjögren's syndrome androgen-deficient? J Rheumatol (2003) 0.89
Temporal analysis of E2 transcriptional induction of PTP and MKP and downregulation of IGF-I pathway key components in the mouse uterus. Physiol Genomics (2007) 0.89
Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol (2003) 0.89
Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age. Endocrinology (2012) 0.89
Influence of insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 on bone health: results from the European Male Ageing Study. Calcif Tissue Int (2011) 0.88
Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y). J Clin Endocrinol Metab (2007) 0.87
Perspective: prostate cancer susceptibility genes. Endocrinology (2002) 0.87
Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner Res (2007) 0.87
Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem (2007) 0.86
Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men. J Clin Endocrinol Metab (2010) 0.86
Effect of polymorphisms in selected genes involved in pituitary-testicular function on reproductive hormones and phenotype in aging men. J Clin Endocrinol Metab (2010) 0.86
Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the reconstructed skin models Episkin and full thickness model from Episkin. J Steroid Biochem Mol Biol (2009) 0.85
Binding of RPE65 fragments to lipid monolayers and identification of its partners by glutathione S-transferase pull-down assays. Biochemistry (2006) 0.85
Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells. J Steroid Biochem Mol Biol (2003) 0.84
Comparison of crystal structures of human type 3 3alpha-hydroxysteroid dehydrogenase reveals an "induced-fit" mechanism and a conserved basic motif involved in the binding of androgen. Protein Sci (2005) 0.84
Steroid derivatives as pure antagonists of the androgen receptor. J Steroid Biochem Mol Biol (2012) 0.84
Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology (2002) 0.84
Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig (2010) 0.83
Multiple conformers in active site of human dihydrofolate reductase F31R/Q35E double mutant suggest structural basis for methotrexate resistance. J Biol Chem (2009) 0.83
Role of juxtamembrane and transmembrane domains in the mechanism of natriuretic peptide receptor A activation. Biochemistry (2010) 0.83
Atlas of dihydrotestosterone actions on the transcriptome of prostate in vivo. Prostate (2009) 0.82
Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer (2002) 0.82
Androgens in the maternal and fetal circulation: association with insulin resistance. J Matern Fetal Neonatal Med (2012) 0.82
Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. Biochim Biophys Acta (2004) 0.82
Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5α-reductase. Horm Mol Biol Clin Investig (2010) 0.82
Serum estradiol is associated with lean mass in elderly Swedish men. Eur J Endocrinol (2010) 0.82
The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes Res (2003) 0.82
Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol (2006) 0.82
Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab (2007) 0.81
Mouse 17alpha-hydroxysteroid dehydrogenase (AKR1C21) binds steroids differently from other aldo-keto reductases: identification and characterization of amino acid residues critical for substrate binding. J Mol Biol (2007) 0.81
Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal, and combined androgen blockade conditions. J Clin Endocrinol Metab (2004) 0.81
Influence of bone remodelling rate on quantitative ultrasound parameters at the calcaneus and DXA BMDa of the hip and spine in middle-aged and elderly European men: the European Male Ageing Study (EMAS). Eur J Endocrinol (2011) 0.81
Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line. J Invest Dermatol (2009) 0.81
Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors. J Lipid Res (2005) 0.81
Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J Med Chem (2005) 0.81
Androgen receptor as a potential sign of prostate cancer metastasis. Prostate (2009) 0.80